Just Herbs' ₹100 crore revenue run rate resurfaces: brand grew 5X in 3 years after Marico takeover

Resurfacing a June 2024 milestone, Indian beauty brand Just Herbs had grown fivefold to a ₹100 crore revenue run rate in the three years since its acquisition by Marico, signalling the scale-up potential of strategic backing in D2C beauty.

— FiledThu, 23 Jul, 2026, 03:06 IST·First seen Thu, 23 Jul, 2026, 03:05 IST·Source Inc42 · Quick Commerce

What happened

Indian beauty brand Just Herbs grew fivefold to an INR 100 crore revenue run rate within three years after Marico acquired it, highlighting post-acquisition

Key facts

  • 5X growth
  • INR 100 Cr revenue run rate
  • 3 years

Why this matters

Marico’s Just Herbs outcome strengthens the case for acquiring culturally resonant, early-stage beauty brands with product differentiation and using the parent’s platform to unlock scale.

What to watch

  • Annual revenue growth sustaining above 30% after reaching the ₹100 crore run rate.
  • Offline store count, modern-trade doors and the share of sales outside D2C channels.
  • Repeat purchase rate, average order value and customer-acquisition-cost trends.
  • New-category launches and their ability to create hero SKUs beyond core Ayurvedic positioning.
  • Marico disclosures on Just Herbs profitability, advertising spend, distribution expansion or additional beauty acquisitions.
  • Competitive responses from other FMCG-backed Ayurveda and masstige beauty brands.
  • Expand modern trade, pharmacy, salon and regional general-trade distribution while preserving premium brand positioning.
  • Launch higher-repeat products in haircare, sunscreen, body care and problem-solution skincare to deepen customer lifetime value.
  • Use Marico's consumer data and media scale to reduce reliance on performance marketing and improve contribution margins.
  • Build selective export and marketplace distribution in Indian-diaspora beauty markets.
  • Consider premiumisation through dermatologist-led claims, ingredient transparency and higher-margin kits or regimens.